Evofem Biosciences, Inc. EVFM

Full chart Compare
Set alert

Price alert · EVFM

All alert types
0.01 USD 0.00 (+1.67%)

Nov 3, 2026, 1:20 PM EST

0.0061 Day range 0.0063
0.001 52-week range 0.014
YTD
-39.00%
1 year
-32.22%

Analyst view

Consensus: buy

Buy
Price target (mean) 11.05 +181047.5% upside
Target (low)
0.75
Target (mean)
11.05
Target (high)
45.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 1
  • 1 month ago 5
  • 2 months ago 5
  • 3 months ago 1

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

EVFM analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.44-0.68 – -0.21-7.20+93.9%8.70M+156.6%2
Next quarter-0.44-0.74 – -0.15-4.95+91.1%11.00M+208.1%2
Current year-3.41-3.90 – -2.93-23.70+85.6%30.57M+271.7%2
Next year-0.67-1.40 – -0.29-3.41+80.4%64.54M+111.1%4

Upgrades and downgrades

The latest rating changes

EVFM analyst upgrades and downgrades
DateFirmActionFromTo
Aug 15, 2022HC Wainwright & Co.Maintained—Buy
Jul 15, 2022Morgan StanleyMaintained—Underweight
Jun 2, 2022Laidlaw & Co.Initiated—Buy
May 25, 2022Piper SandlerMaintained—Overweight
May 11, 2022Morgan StanleyMaintained—Underweight
May 10, 2022Morgan StanleyMaintained—Underweight
Apr 12, 2022Morgan StanleyMaintained—Underweight
Mar 4, 2022Morgan StanleyMaintained—Underweight
Nov 16, 2021HC Wainwright & Co.Maintained—Buy
Oct 21, 2021HC Wainwright & Co.Maintained—Buy
Oct 14, 2021Morgan StanleyDowngradeEqual-WeightUnderweight
Aug 12, 2021Morgan StanleyMaintained—Equal-Weight
Jun 7, 2021HC Wainwright & Co.Maintained—Buy
Mar 8, 2021HC Wainwright & Co.Maintained—Buy
Oct 2, 2020StifelInitiated—Buy
Aug 20, 2020Morgan StanleyInitiated—Equal-Weight
Jun 9, 2020HC Wainwright & Co.Maintained—Buy
Jun 8, 2020Piper SandlerInitiated—Overweight
May 27, 2020OppenheimerMaintained—Outperform
Dec 11, 2019H.C. WainwrightReiterated—Buy
Sep 26, 2018Cantor FitzgeraldInitiated—Overweight
Jun 27, 2018RBC CapitalInitiated—Outperform
Jun 18, 2018OppenheimerInitiated—Outperform
Mar 19, 2018H.C. WainwrightInitiated—Buy